Depo-Provera and Black Women: The Health Equity Crisis Behind the Brain Tumor Lawsuit

When the Depo-Provera brain tumor lawsuit is described as a women's health crisis, that description is accurate — but incomplete. The full picture requires confronting an uncomfortable truth that has been largely absent from mainstream coverage of MDL 3140: Black women used Depo-Provera at nearly double the national average. And the history of how this drug was developed, tested, and marketed reveals a pattern of racial disparity that did not begin in 2024.

This is a story about the Depo-Provera lawsuit. But it is also a story about whose health gets protected, whose risks get disclosed, and who bears the burden when a pharmaceutical company stays silent for decades.

1. By the Numbers: The Racial Disparity in Depo-Provera Use

The data on who used Depo-Provera in the United States is stark. According to CDC data from 2015 to 2019:

This disparity is not explained by preference alone. Research and health advocates identify multiple structural drivers: limited access to a full range of contraceptive options in under-resourced communities, targeted marketing by pharmaceutical companies and healthcare systems, provider bias in recommending long-acting contraceptives to patients of color, and a legacy of medical racism that shaped both the drug's development and its distribution.

The practical consequence: because Black women used Depo-Provera at substantially higher rates, they were exposed to the meningioma risk at substantially higher rates — without any warning that this risk existed until December 2025.

2. The History: Grady Clinic and Non-Consensual Testing

To understand the racial dynamics of the Depo-Provera lawsuit, it is necessary to understand how the drug was developed. Depo-Provera's active ingredient, medroxyprogesterone acetate (MPA), was synthesized in 1954 by scientists at the Upjohn Company — which would later become part of Pfizer. Clinical trials for contraceptive use began in the 1960s.

Those trials took place at multiple sites across the United States. One of the most documented was the Grady Memorial Hospital clinic in Atlanta, Georgia. Health advocates and medical historians have documented that approximately 50% of research subjects at some trial sites were low-income Black women — and that the informed consent processes at these sites were frequently inadequate or absent.

This history is not simply a moral reckoning — it has direct legal relevance. It establishes that the disparate impact of Depo-Provera on Black women was not an accident. It was built into the drug's development process from the beginning.

3. The 1992 FDA Approval Black Women's Groups Opposed

On October 29, 1992, the FDA approved Depo-Provera for contraceptive use in the United States. The approval came despite formal opposition from multiple women's health organizations, including the National Black Women's Health Project — one of the most prominent reproductive health advocacy organizations in the country at the time.

The National Black Women's Health Project's opposition was rooted in two concerns that have proven remarkably prescient:

Both concerns proved prescient. The drug was approved. Usage rates among Black women climbed to 41.2% — nearly double the national average. And the meningioma risk that advocates feared might be lurking in the safety data turned out to be real.

4. How Depo-Provera Was Marketed to Black and Low-Income Women

The racial disparity in Depo-Provera usage is not simply a product of organic preference. It reflects decades of deliberate marketing strategy and structural barriers that limited alternatives:

• Clinic-based distribution concentrated in low-income areas. Depo-Provera's injectable format made it particularly suited for distribution through public health clinics and community health centers — institutions that disproportionately serve Black and low-income women. Unlike birth control pills that required a pharmacy and insurance coverage for monthly fills, a single quarterly injection could be administered in one clinic visit, making it operationally convenient for healthcare systems managing high patient volumes.
• Provider recommendation bias. Multiple studies have documented that healthcare providers are more likely to recommend long-acting reversible contraceptives or injectables to patients of color and low-income patients than to white or higher-income patients offered the same range of options. This pattern — sometimes called "provider coercion" by reproductive rights advocates — shaped who received Depo-Provera recommendations.
• Lack of access to alternatives. Women with limited insurance coverage often had fewer access points for IUDs, implants, or oral contraceptives requiring regular prescriptions. Depo-Provera, available through public health funding at community clinics, filled that gap — not because it was the best option for every patient, but because it was often the most accessible option.
• Pharmaceutical industry marketing. Research has documented that Depo-Provera was "long marketed to women of color, particularly Black and Hispanic women, framed as a convenient solution to unintended pregnancies" — language that reproductive health advocates argue stigmatizes these communities while obscuring the availability of safer alternatives.

5. What the Meningioma Risk Means for Black Women Today

The 2024 BMJ study established that long-term Depo-Provera users (12+ months) face a 5.55-fold increased risk of developing meningioma brain tumors compared to non-users. The American College of Obstetricians and Gynecologists (ACOG) translated this to population terms: the risk of meningioma increases from roughly 1 in 10,000 women to 5 in 10,000 women using the drug long-term.

Because Black women used Depo-Provera at 41.2% — nearly double the 24.5% national average — the absolute population of Black women who may have experienced elevated meningioma risk is disproportionately large. This is not a statistical abstraction. It means that in Black communities across America, women who used Depo-Provera for years are now at elevated risk of a brain tumor diagnosis that they were never warned about.

6. Systemic Barriers That Kept Warnings From Reaching Black Patients

Even if a meningioma warning had appeared on the Depo-Provera label earlier, systemic barriers would have limited its reach to Black patients. Understanding these barriers matters both for the current lawsuit and for evaluating what accountability looks like.

7. Legal Options for Black Women Who Used Depo-Provera

The racial disparities described in this article do not change the legal eligibility requirements for the Depo-Provera meningioma lawsuit — but they provide important context for why this litigation matters disproportionately for Black women and their families.

To qualify for a Depo-Provera meningioma lawsuit, a woman generally needs to establish:

• She used Depo-Provera (or a generic medroxyprogesterone acetate injection) for at least 12 months, or received at least 4 injections
• She was diagnosed with a meningioma (brain or spinal tumor arising from the meninges)
• Her claim falls within the applicable statute of limitations in her state (generally measured from the date of diagnosis or from when she reasonably should have connected her diagnosis to Depo-Provera use)

Race, income level, and the circumstances under which someone began using Depo-Provera do not affect eligibility. However, they are relevant context for understanding the scope of harm and for evaluating whether the marketing and prescription practices that led to disproportionate Black women's use constitute additional claims.

Attorneys handling Depo-Provera cases offer free case evaluations with no upfront cost. Given that Black women represent a disproportionate share of long-term Depo-Provera users, they may represent a significant share of eligible claimants in MDL 3140.

Frequently Asked Questions